Amenal Pharmaceuticals Co., Ltd. - A 2025 Q1 report

Washington, D.C. 20549 Form10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934For the quarterly period endedMarch 31, 2025OR ☐OF 1934For the transition period from Amneal Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware93-4225266(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)Amneal Pharmaceuticals, Inc. Title of each classClass A Common Stock, par value $0.01 pershare Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, oran emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth Large accelerated filer Non-accelerated filer If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with anynew or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ As of April30, 2025, there were313,419,599shares of the registrant’s Class A common stock outstanding, with a par value of $0.01. Amneal Pharmaceuticals, Inc.Table of Contents Cautionary Note Regarding Forward-Looking Statements PART I - FINANCIAL INFORMATIONItem 1.Financial Statements (Unaudited)Consolidated Statements of OperationsConsolidated Statements of ComprehensiveLossConsolidated Balance SheetsConsolidated Statements of Cash FlowsConsolidated Statements of Changes in Stockholders’(Deficiency) EquityNotes to Consolidated Financial StatementsItem 2.Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3.Quantitative and Qualitative Disclosures About Market RiskItem 4.Controls and Procedures PART II - OTHER INFORMATIONItem 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.Exhibits Signatures Cautionary Note Regarding Forward-Looking Statements This Quarterly Report on Form 10-Q and other publicly available documents of Amneal Pharmaceuticals, Inc. contain “forward-looking statements” within the meaning of the safe harbor provisions of the United States (“U.S.”) Private Securities LitigationReform Act of 1995. Management and representatives of Amneal Pharmaceuticals, Inc. and its subsidiaries (“the Company”, “we”,“us”, or “our”) also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly tohistorical or current facts and reflect management’s assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as “plans,” “expects,” “will,” “anticipates,” “targets,” “estimates,” andother words of similar meaning in conjunction with, among other things: discussions of future operations; expected operating results Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they aresubject to uncertainties, risks and changes that are difficult to predict and many of which are outside of our control. Investors shouldrealize that if underlying assumptions prove inaccurate, known or unknown risks or uncertainties materialize, or other factors orcircumstances change, our actual results and financial condition could vary materially from expectations and projections expressed or Summary of Material Risks Risks and uncertainties that make an investment in the Company speculative or risky or that could cause our actual results to differmaterially from the forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to: •our ability to successfully develop, license, acquire and commercialize new products on a timely basis;•the competition we face in the pharmaceutical industry from brand and generic drug product companies, and the impact ofthat competition on our ability to set prices;•our ability to obtain exclusive marketing rights for our products;•the impact of illegal distribution and sale by third parties of counterfeit versions of our products or stolen products;•the impact of negative market perceptions of us and the s